Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease.

Zonozi, Reza; Wallace, Zachary S; Laliberte, Karen; Huizenga, Noah R; Rosenthal, Jillian M; Rhee, Eugene P; Cortazar, Frank B; Niles, John L

Zonozi, Reza; Wallace, Zachary S; Laliberte, Karen; Huizenga, Noah R; Rosenthal, Jillian M; Rhee, Eugene P; Cortazar, Frank B; Niles, John L.

Affiliation

Zonozi R; Massachusetts General Hospital, Boston.
Wallace ZS; Massachusetts General Hospital, Boston.
Laliberte K; Massachusetts General Hospital, Boston.
Huizenga NR; Massachusetts General Hospital, Boston.
Rosenthal JM; Massachusetts General Hospital, Boston.
Rhee EP; Massachusetts General Hospital, Boston.
Cortazar FB; Massachusetts General Hospital, Boston, and New York Nephrology Vasculitis and Glomerular Center, Albany.
Niles JL; Massachusetts General Hospital, Boston.

Arthritis Rheumatol ; 73(2): 347-354, 2021 02.

Article de En | MEDLINE | ID: mdl-32892495

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Maladies auto-immunes / Sepsie / Fièvre / Rituximab / Facteurs immunologiques / Neutropénie Type d'étude: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Adult / Aged / Female / Humans / Male / Middle aged Langue: En Journal: Arthritis Rheumatol Année: 2021 Type de document: Article Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google